After some major hiccups last year, new breakthroughs suggest CRISPR is becoming a mainstay in healthcare. The technology is now being deployed to try to cure the most common causes of death, including heart disease and even cancer. But, the race to produce one-dose DNA-tweaking treatments has also highlighted the necessity to develop anti-CRISPR drugs to limit the technology’s impact if used as a weapon of mass destruction.
To read this Market Insight, you’ll need to sign in
If you don’t have a subscription, sign up or start a free trial .
